Halozyme Therapeutics, Inc.
General ticker "HALO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $6.1B
Halozyme Therapeutics, Inc. follows the US Stock Market performance with the rate: 50.8%.
Estimated limits based on current volatility of 1.4%: low 46.57$, high 48.19$
Factors to consider:
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [33.16$, 51.81$]
- 2024-12-30 to 2025-12-30 estimated range: [34.39$, 54.11$]
Financial Metrics affecting the HALO estimates:
- Positive: Non-GAAP EPS, $ of 2.78 > 2.29
- Positive: Return on assets ratio (scaled to [-100,100]) of 13.98 > 7.10
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Positive: Operating profit margin, % of 40.71 > 19.51
- Positive: Inventory ratio change, % of 0.54 <= 1.08
- Positive: -0.96 < Investing cash flow per share, $ of -0.73
- Positive: 7.18 < Operating cash flow per share per price, % of 7.50
Short-term HALO quotes
Long-term HALO plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $443.31MM | $660.12MM | $829.25MM |
| Operating Expenses | $167.41MM | $392.58MM | $491.68MM |
| Operating Income | $275.90MM | $267.53MM | $337.57MM |
| Non-Operating Income | $-27.38MM | $-18.61MM | $10.76MM |
| Interest Expense | $7.53MM | $16.95MM | $18.76MM |
| R&D Expense | $35.67MM | $66.61MM | $76.36MM |
| Income(Loss) | $248.52MM | $248.92MM | $348.33MM |
| Taxes | $-154.19MM | $46.79MM | $66.73MM |
| Profit(Loss) | $402.71MM | $202.13MM | $281.59MM |
| Stockholders Equity | $196.95MM | $169.80MM | $83.81MM |
| Inventory | $53.91MM | $100.12MM | $127.60MM |
| Assets | $1,104.43MM | $1,841.51MM | $1,733.27MM |
| Operating Cash Flow | $299.44MM | $240.11MM | $388.57MM |
| Capital expenditure | $1.46MM | $4.81MM | $15.29MM |
| Investing Cash Flow | $-406.29MM | $-487.00MM | $-96.91MM |
| Financing Cash Flow | $77.86MM | $362.37MM | $-407.99MM |
| Earnings Per Share* | $2.86 | $1.48 | $2.13 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.